UNSPSC 51131626: Camonagrel

This classification denotes an antiplatelet agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier XM930M133O. European Medicines Agency schedules Camonagrel in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06065MIG. Camonagrel generally arises in the molecular formula C15H16N2O3. The term CAMONAGREL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 4, no. 3 1990, list 30.) Most nations schedule camonagrel under HS 29332990 and SITC 51573.

As of Q4 2014, CAMONAGREL remains the US FDA Preferred Term for this commodity. Camonagrel bears US NLM identifiers UMLS ID C0534183 and NCI Concept Code C76006. SMILES: O(C1CC2CCC(C2CC1)C(=O)O)CCN1CCNC1.

UNSPSC 51131626 Camonagrel, a Commodity code, describes a specific pharmaceutical product for which state and local governments do not currently show substantive procurement activity. The single recent opportunity tagged to this code — Sourcewell RFP #061626, posted May 12, 2026 with a June 16, 2026 response deadline — solicits law enforcement equipment on behalf of a multistate cooperative purchasing network encompassing counties, municipalities, school districts, and other public entities across Washington state and the United States. The mismatch between the code's pharmaceutical scope and the actual solicitation content (tactical and operational law enforcement gear) indicates that the code has been misapplied or misfiled in this instance and does not reflect genuine procurement demand for camonagrel at the state and local level.

The geographic footprint of the single recent opportunity includes Washington state (Franklin, Grant, Grays Harbor, Chelan, and Yakima counties) with participation extended nationwide through Sourcewell's cooperative framework, though the substance of the opportunity remains law enforcement equipment rather than pharmaceutical procurement. Given the absence of authentic camonagrel-specific opportunities in the recent record, this code does not present a meaningful procurement pipeline for vendors specializing in this pharmaceutical product at present.